| Year |
Title |
Altmetric |
| 2021
|
Calming the cytokine storm in COVID-19.
Nature Medicine.
27:1674-1675.
2021
|
|
| 2021
|
Drs. Cron and Chatham reply.
Journal of Rheumatology.
48:1345-1346.
2021
|
|
| 2021
|
Depleting plasmacytoid dendritic cells reduces local type i interferon responses and disease activity in patients with cutaneous lupus.
Science Translational Medicine.
13.
2021
|
|
| 2021
|
Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.
Arthritis and Rheumatology.
73:816-825.
2021
|
|
| 2021
|
Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition.
Lupus.
30:795-806.
2021
|
|
| 2021
|
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.
Arthritis and Rheumatology.
73:e1-e12.
2021
|
|
| 2021
|
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Arthritis and Rheumatology.
73:121-131.
2021
|
|
| 2020
|
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.
RMD Open.
6.
2020
|
|
| 2020
|
Drs. cron and chatham reply.
Journal of Rheumatology.
47:1723.
2020
|
|
| 2020
|
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort.
Arthritis and Rheumatology.
72:1734-1740.
2020
|
|
| 2020
|
Drs. Cron and Chatham reply.
Journal of Rheumatology.
47:1590-1591.
2020
|
|
| 2020
|
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial.
Lancet Rheumatology.
2:e613-e622.
2020
|
|
| 2020
|
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2.
Arthritis and Rheumatology.
72:e1-e12.
2020
|
|
| 2020
|
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
Arthritis and Rheumatology.
72:1241-1251.
2020
|
|
| 2020
|
Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine.
Lupus.
29:1095-1105.
2020
|
|
| 2020
|
The Rheumatologist's Role in COVID-19.
Journal of Rheumatology.
47:639-642.
2020
|
|
| 2020
|
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
Journal of Autoimmunity.
106.
2020
|
|
| 2019
|
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
Arthritis and Rheumatology.
71:1125-1134.
2019
|
|
| 2019
|
Ifnγ induces epigenetic programming of human t-bethi b cells and promotes tlr7/8 and il-21 induced differentiation.
eLife.
8.
2019
|
|
| 2019
|
Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.
PLoS Medicine.
16.
2019
|
|
| 2019
|
Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
Journal of Rheumatology.
46:492-500.
2019
|
|
| 2018
|
Cutting edge: Intracellular IFN-β and distinct type i IFN expression patterns in circulating systemic lupus erythematosus B cells.
Journal of Immunology.
201:2203-2208.
2018
|
|
| 2018
|
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.
Arthritis Care and Research.
70:1478-1487.
2018
|
|
| 2017
|
A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.
Lupus.
26:1483-1490.
2017
|
|
| 2017
|
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Arthritis and Rheumatology.
69:362-375.
2017
|
|
| 2016
|
Extensive Pyoderma Gangrenosum Associated with Granulomatosis with Polyangiitis with Both Responsive to Rituximab
2016
|
|
| 2016
|
A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis.
Journal of Immunology.
196:2492-2503.
2016
|
|
| 2016
|
Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial∗.
Critical Care Medicine.
44:275-281.
2016
|
|
| 2016
|
Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes.
Clinical and Experimental Rheumatology.
34:953.
2016
|
|
| 2015
|
Minorities with lupus nephritis and medications: A study of facilitators to medication decision-making
2015
|
|
| 2015
|
Convergent Validity of New Disease Assessment Instruments (Dai) In Systemic Lupus Erythematosus (Sle) In Relation to Sledai-2k..
Value in Health.
18:A677.
2015
|
|
| 2015
|
Barriers to medication decision making in women with lupus nephritis: A formative study using nominal group technique.
Journal of Rheumatology.
42:1616-1623.
2015
|
|
| 2015
|
Does viral hemorrhagic fever represent reactive hemophagocytic syndrome?.
Journal of Rheumatology.
42:1078-1080.
2015
|
|
| 2015
|
Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus.
Arthritis and Rheumatology.
67:1848-1857.
2015
|
|
| 2015
|
Vasculitis related to viral and other microbial agents.
Best Practice and Research: Clinical Rheumatology.
29:226-243.
2015
|
|
| 2014
|
Cell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurements.
Lupus Science & Medicine.
1.
2014
|
|
| 2014
|
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Journal of Rheumatology.
41:300-309.
2014
|
|
| 2014
|
Macrophage Activation Syndrome Secondary to Human Monocytic Ehrlichiosis.
Indian Journal of Hematology and Blood Transfusion.
30:145-147.
2014
|
|
| 2013
|
Genome-Wide DNA Methylation Analysis of Systemic Lupus Erythematosus Reveals Persistent Hypomethylation of Interferon Genes and Compositional Changes to CD4+ T-cell Populations.
PLoS Genetics.
9.
2013
|
|
| 2012
|
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Arthritis and Rheumatism.
64:4040-4047.
2012
|
|
| 2012
|
Device for carrying blood samples at 37°C for cryoglobulin test
2012
|
|
| 2012
|
Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
Journal of Rheumatology.
39:1632-1640.
2012
|
|
| 2012
|
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Arthritis and Rheumatism.
64:2328-2337.
2012
|
|
| 2012
|
2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Arthritis Care and Research.
64:625-639.
2012
|
|
| 2012
|
Systemic lupus erythematosus: Genomics, mechanisms, and therapies.
Clinical and Developmental Immunology.
2012.
2012
|
|
| 2011
|
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Arthritis and Rheumatism.
63:3918-3930.
2011
|
|
| 2011
|
B lymphocytes are resistant to death receptor 5-induced apoptosis.
Clinical Immunology.
139:21-31.
2011
|
|
| 2010
|
Report of the American College of Rheumatology Pain Management Task Force.
Arthritis Care and Research.
62:590-599.
2010
|
|
| 2010
|
Rheumatic manifestations of systemic disease: Sarcoidosis.
Current Opinion in Rheumatology.
22:85-90.
2010
|
|
| 2009
|
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Arthritis Care and Research.
61:1168-1178.
2009
|
|
| 2009
|
Novel evidence-based systemic lupus erythematosus responder index.
Arthritis Care and Research.
61:1143-1151.
2009
|
|
| 2009
|
Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis.
Scandinavian Journal of Immunology.
70:309-316.
2009
|
|
| 2009
|
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.
Journal of Clinical Investigation.
119:1668-1677.
2009
|
|
| 2008
|
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus
2008
|
|
| 2008
|
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Arthritis and Rheumatism.
58:2453-2459.
2008
|
|
| 2008
|
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Care and Research.
59:762-784.
2008
|
|
| 2006
|
Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? Commentary.
Nature Clinical Practice Rheumatology.
2:240-241.
2006
|
|
| 2006
|
Improving ambulatory prescribing safety with a handheld decision support system: A randomized controlled trial.
Journal of the American Medical Informatics Association.
13:171-179.
2006
|
|
| 2006
|
Research Paper: Improving Ambulatory Prescribing Safety with a Handheld Decision Support System: A Randomized Controlled Trial.
2006
|
|
| 2006
|
Ultrasound appearance of knuckle pads.
2006
|
|
| 2005
|
Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
Arthritis and Rheumatism.
52:3943-3954.
2005
|
|
| 2003
|
FcγRIIIb Allele-Sensitive Release of α-Defensins: Anti-Neutrophil Cytoplasmic Antibody-Induced Release of Chemotaxins.
Journal of Immunology.
171:6090-6096.
2003
|
|
| 2002
|
Normal radiographs in patients with persistent "hip pain" - Value of magnetic resonance imaging.
Journal of Rheumatology.
29:2463-2465.
2002
|
|
| 2002
|
Immune function in patients with rheumatoid arthritis treated with etanercept.
Clinical Immunology.
103:13-21.
2002
|
|
| 2001
|
Treatment of lupus with corticosteroids.
Lupus.
10:140-147.
2001
|
|
| 2000
|
Renal failure: A risk factor for methotrexate toxicity.
Arthritis and Rheumatism.
43:1185-1186.
2000
|
|
| 2000
|
Renal failure: a risk factor for methotrexate toxicity..
Arthritis and Rheumatism.
43:1185-1186.
2000
|
|
| 1999
|
Update on sarcoidosis.
Current Opinion in Rheumatology.
11:83-87.
1999
|
|
| 1998
|
Ligation of CR1 attenuates Fc receptor-mediated myeloperoxidase release and HOCl production by neutrophils.
Journal of Leukocyte Biology.
63:477-485.
1998
|
|
| 1996
|
Acidic fibroblast growth factor (FGF-1) enhances huvec expression of ICAM-1 induced by IL-1β.
The FASEB Journal.
10.
1996
|
|
| 1996
|
Characterization of PepB, a group B streptococcal oligopeptidase.
Infection and Immunity.
64:3401-3406.
1996
|
|
| 1995
|
Effects of tenidap on superoxide-generating enzymes. Non-competitive inhibition of xanthine oxidase.
Biochemical Pharmacology.
50:811-814.
1995
|
|
| 1995
|
Activation of human neutrophils by surface-associated IgA is associated with the release of activated collagenase..
Clinical immunology and immunopathology.
76:241-247.
1995
|
|
| 1995
|
Activation of human neutrophils by surface-associated IgA is associated with the release of activated collagenase.
Clinical immunology and immunopathology.
76:241-247.
1995
|
|
| 1995
|
Progressive joint destruction in a human immunodeficiency virus‐infected patient with rheumatoid arthritis.
Arthritis and Rheumatism.
38:1328-1332.
1995
|
|
| 1995
|
Rheumatoid synovial fibroblast adhesion to human articular cartilage.
Arthritis and Rheumatism.
38:1694-1700.
1995
|
|
| 1994
|
Determinants of neutrophil HOCl generation: Ligand-dependent responses and the role of surface adhesion.
Journal of Leukocyte Biology.
56:654-660.
1994
|
|
| 1994
|
HOCl production by human neutrophils activated by surface-associated IgG: Requirement for influx of extracellular calcium.
Journal of Leukocyte Biology.
55:793-797.
1994
|
|
| 1993
|
Degradation of human articular cartilage by neutrophils in synovial fluid.
Arthritis and Rheumatism.
36:51-58.
1993
|
|
| 1993
|
Fixation of C3 to IgG attenuates neutrophil HOCl generation and collagenase activation.
Journal of Immunology.
151:949-958.
1993
|
|
| 1992
|
Additive enhancement of neutrophil collagenase activity by HOCl and cathepsin G.
Biochemical and Biophysical Research Communications.
184:560-567.
1992
|
|
| 1992
|
Ligand dependent release of activated neutrophil collagenase--a role for surface bound IgG in the degradation of articular collagens..
Matrix (Stuttgart, Germany). Supplement.
1:207-208.
1992
|
|
| 1991
|
Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase.
Arthritis and Rheumatism.
34:211-216.
1991
|
|
| 1990
|
Letter to the editor (I).
Arthritis and Rheumatism.
3:104-105.
1990
|
|
| 1990
|
Letter to the editor (I).
Arthritis and Rheumatism.
3:104-105.
1990
|
|
| 1990
|
Letters.
Arthritis and Rheumatism.
3:104-105.
1990
|
|
| 1990
|
Ligand‐dependent release of active neutrophil collagenase.
Arthritis and Rheumatism.
33:228-234.
1990
|
|
| 1990
|
Lysis of fibrillar collagen by neutrophils in synovial fluid. A Role for Surface‐Bound Immunoglobulins.
Arthritis and Rheumatism.
33:1333-1339.
1990
|
|
| 1989
|
Valvular Heart Disease in Systemic Lupus Erythematosus.
New England Journal of Medicine.
320:739-741.
1989
|
|
| 1989
|
Intraarticular corticosteroid injections: Should we rest the joints?.
Arthritis and Rheumatism.
2:70-74.
1989
|
|
| 1989
|
Intraarticular corticosteroid injections: Should we rest the joints?.
Arthritis and Rheumatism.
2:70-74.
1989
|
|
| 1989
|
The reply.
American Journal of Medicine.
86:634.
1989
|
|
| 1988
|
Cell Surface Receptors for Kidney Basement Membranes.
American Journal of Kidney Diseases.
12:78-83.
1988
|
|
| 1988
|
Clinically significant valvular heart disease in systemic lupus erythematosus.
American Journal of Medicine.
85:645-650.
1988
|
|
| 1983
|
Leukemoid Blood Reaction to Tetracycline.
Southern Medical Journal.
76:1195-1196.
1983
|
|
